Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (3292 companies, A–Z).
Viridian Therapeutics reported positive phase 1 results for VRDN-008, an extended half-life FcRn inhibitor given subcutaneously, in six healthy volunteers. The company plans to focus its FcRn clinical development on VRDN-008 and to start at least one pivotal trial in 2027, beginning with myasthenia gravis in mid-2027, pending regulatory feedback.
Six healthy volunteers; IgG reduction of 74% at peak and sustained through eight weeks after subcutaneous dosing
Extended half-life of 15 to 18 days, five to six times longer than first-generation Fc fragments
First pivotal trial planned to start in mid-2027 in myasthenia gravis, pending regulatory feedback
Company plans to focus FcRn development on VRDN-008 and may pursue VRDN-006 in the future
Cullinan Therapeutics furnished a press release and 8-K describing interim clinical data from a Phase 1b/2a trial of velinotamig in patients with refractory systemic lupus erythematosus. The trial is run by Genrix in China, and Cullinan holds the global (ex-Greater China) license, so the results bear on the company's lead clinical asset, though the data are early and based on a small number of patients.
As of the September 8, 2026 data cutoff, 12 patients had been treated across three multi-dose cohorts, with no dose-limiting toxicities and no ICANS reported
Cytokine release syndrome occurred in two patients, limited to Grade 1 or 2 events; no Grade 3 or higher CRS was observed
Eight of nine evaluable patients achieved a reduction of at least four points in SLEDAI-2K
Four of seven evaluable patients with proteinuria above 500 mg/24 hours at baseline achieved a complete renal response within 24 weeks
Faeth Therapeutics reported preliminary topline results from its Phase 2 PIK-201 trial of PIKTOR with paclitaxel in 42 treated patients with advanced endometrial cancer, using an October 30, 2026 efficacy data cut. The confirmed objective response rate was 33% (12 of 36 efficacy-evaluable patients) and preliminary median progression-free survival was 7.4 months, and the company said the data support advancing to a Phase 3 trial. The results are preliminary, the trial is single-arm, and 64% of patients had a grade 3 or higher treatment-related adverse event.
Confirmed ORR of 33% (12 of 36); unconfirmed ORR of 36% (13 of 36); 44% confirmed ORR (7 of 16) in patients with a PIK3CA mutation
Preliminary median PFS of 7.4 months (95% CI 5.3 to NR); 6-month PFS rate of 62%
64% of patients had a grade 3 or higher treatment-related adverse event; 2 patients (5%) discontinued due to treatment-related adverse events; no treatment-related deaths
Company webcast held November 9, 2026 at 8:00 a.m. ET
Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in 42 patients with obstructive hypertrophic cardiomyopathy (oHCM) at the American Heart Association Scientific Sessions 2026. The company reported gains in exercise capacity, symptoms and LVOT gradient, and also presented diastolic function data in non-obstructive HCM. The filing contains no financial results, and the company will hold an investor event today to discuss the data and a planned fixed-dose oHCM study.
At Week 52, peak oxygen uptake rose a mean of 2.7 mL/kg/min and KCCQ-CSS rose a mean of 17.3 points from OLE baseline.
At Week 52, 79% (33/42) of patients achieved a Valsalva LVOT gradient below 30 mmHg.
Two patients had transient LVEF reductions below 50%, and no on-treatment severe or serious adverse events were reported.
Investor event and webcast scheduled for November 6, 2026, at 3:35 p.m. CT (4:35 p.m. ET).
Pulse Biosciences reported interim six-month results from its PRECISE-BTN study of the nPulse Vybrance system for symptomatic benign thyroid nodules, presented at the American Thyroid Association meeting. In the interim dataset of 43 patients, 86% achieved at least 50% nodule volume reduction at six months, and no serious adverse events were reported. The results are early, cover a subset of the study's enrolled patients, and do not include financial figures.
86% of the 43 evaluated patients achieved at least 50% nodule volume reduction at six months, the primary endpoint
Median volume reduction was 72% at six months, with most reduction evident by the one-month visit
ThyPRO-39 quality of life score improved 78% from baseline; 82% of patients with baseline neck pressure or fullness reported full resolution at six months
No serious adverse events were reported; the company expects to report full six-month and 12-month data for all patients
Home BancShares said it received about $80.7 million from the borrower's sale of part of the collateral securing a $92.1 million non-performing loan relationship in its Texas market, completing the first phase of resolving the credit. The payment lowers the company's non-performing loan and asset ratios and leaves about $11.4 million in carrying amount, with a second phase expected in the fourth quarter of 2026 that could recover part of an amount charged off in 2024.
Payment of about $80.7 million received; proceeds were about 95% of the appraised value of the collateral sold
Remaining carrying amount of about $11.4 million, still classified as nonaccrual pending the second phase
Based on September 30, 2026 balances, non-performing loans to total loans fall about 48 basis points and non-performing assets to total assets fall about 34 basis points
Second phase expected to complete in the fourth quarter of 2026, but the company gives no assurance the remaining balance will be repaid as expected
Northwest Bancshares furnished an investor presentation under Item 7.01 for its participation in the 2026 Hovde Financial Services Conference on November 5, 2026. The deck, dated November 4, 2026, reports third-quarter 2026 revenue of $184.9 million, which the company describes as a record quarter, and diluted EPS of $0.34 (adjusted EPS $0.35).
Conference participation: 2026 Hovde Financial Services Conference on Thursday, November 5, 2026; presentation dated November 4, 2026 (Exhibit 99.1)
3Q26 revenue of $184.9 million, up 9.9% year over year and 2.0% quarter over quarter; net interest income of $149.0 million, up 9.5% year over year
3Q26 diluted EPS of $0.34 and adjusted diluted EPS of $0.35; total loans of $13.3 billion and total deposits of $14.3 billion as of September 30, 2026
Moleculin Biotech announced that an abstract on interim results from its pivotal MB-108 Phase 2/3 trial of Annamycin has been accepted for poster presentation at the 2026 American Society of Hematology Annual Meeting, held December 12-15, 2026 in New Orleans. The data cover the first 45 randomized patients, so the results are early and preliminary, and the independent Data Monitoring Committee recommended the study continue without amendment.
Complete remission rates were 43% and 36% in the two Annamycin arms, versus 12% in the placebo arm, among the first 45 randomized patients.
No signs of cardiotoxicity were observed through the data cutoff; cardiac safety data will be reviewed at the second interim analysis.
The second interim analysis is expected in early 2027.
The poster presentation is scheduled at the ASH meeting, December 12-15, 2026.
German American Bancorp will hold investor meetings on November 5, 2026, at the 2026 Hovde Group Financial Services Conference, and furnished a presentation under Item 7.01. The deck reports third-quarter 2026 results, including record quarterly earnings of $1.03 per diluted share, up from $0.94 a year earlier.
Diluted EPS of $1.03 for Q3 2026, versus $0.94 in Q3 2025 and $1.02 in Q2 2026
Net income of $38.6 million for Q3 2026, versus $35.1 million in Q3 2025
Total revenue of $102.2 million for Q3 2026, versus $94.2 million in Q3 2025
Meetings with investors led by Chairman and CEO D. Neil Dauby and President and CFO Bradley M. Rust on November 5, 2026
Oncolytics Biotech reported translational data from a Phase 1/2 study in second-line or later squamous cell anal cancer patients, presented at the SITC 2026 Annual Meeting. The company said pelareorep combined with a checkpoint inhibitor more than doubled the objective response rate and increased median duration of response by 50% versus the current approved therapy in that population, though the immune data rest on small patient numbers.
Seven of eight evaluable patients showed greater than two-fold increases in immune-activation biomarkers after one cycle of therapy
Six of 14 patients evaluated for HPV-16 immune responses showed HPV-16 clonal expansion, and four of those had tumor shrinkage
The company cited a potential $3 to 5 billion market for HPV-associated cancers, based on its internal estimates
Cencora reorganized its operating model and will report three segments starting in fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The company also furnished unaudited revised segment results for fiscal 2026 and 2025 under the new structure, which show total revenue of $337.4 billion and total segment operating income of $4.8 billion for fiscal 2026, up from $321.3 billion and $4.2 billion in fiscal 2025.
Beginning in the first quarter of fiscal 2027, reporting segments are Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other
Fiscal 2026 total revenue was $337,397,299 thousand, compared with $321,332,819 thousand in fiscal 2025
Fiscal 2026 total segment operating income was $4,813,047 thousand, compared with $4,222,973 thousand in fiscal 2025
MWI Animal Health, Profarma and other PharmaLex components are in Other, a non-reportable category where the company is exploring strategic alternatives
FirstCash furnished an November 2026 investor presentation as Exhibit 99.1 to this 8-K and posted it on its website. The deck shows revenue up 18%, GAAP EPS up 25% and adjusted EPS up 19% versus the prior year, and it reiterates the pending Ramsdens acquisition and a 10% dividend increase for shareholders.
Trailing twelve-month figures as of September 30, 2026: revenue of $4.3 billion, GAAP net income of $406 million and adjusted EBITDA of $835 million
Fourth quarter dividend declared at $0.46 per share, a 10% increase over the prior quarterly dividend, annualizing to $1.84 per share
$176 million remains under the $350 million share repurchase program, with 1.6 million shares repurchased year to date at an average price of $201.04
Ramsdens acquisition has an estimated equity value of about $304 million and is targeted to close by the end of 2026, pending antitrust approval
Civista Bancshares furnished its Q3 2026 investor presentation under Regulation FD ahead of its participation in the Hovde Group Financial Services Conference on November 4-6, 2026, in Orlando, Florida. The presentation reports third-quarter net income of $16.0 million, up from $12.8 million a year earlier, and diluted EPS of $0.77, up 13.2% year over year, which shows higher earnings for shareholders.
Q3 2026 net income of $16.0 million, up 25.5% from $12.8 million in Q3 2025
Q3 2026 diluted EPS of $0.77, up 13.2% year over year
Net interest income of $39.4 million, up 14.1% year over year; efficiency ratio improved to 55.3% from 61.4%
Chuck Parcher has served as President and CEO since August 28, 2026, under a planned transition
United States Oil Fund, LP filed its monthly account statement for the month ended September 30, 2026, showing net income of $179,970,315 and net asset value of $1,646,935,704, down from $1,790,469,813 on September 1. Net asset value per share ended the month at $145.44. The filing is a required monthly statement, and the decline in net asset value reflected withdrawals that exceeded additions during the month.
Net income of $179,970,315 on total income of $181,109,185 and total expenses of $1,138,870 for September 2026.
Net asset value fell to $1,646,935,704 at September 30, 2026, from $1,790,469,813 at the start of the month.
Withdrawals of 8,500,000 shares ($1,264,202,703) exceeded additions of 6,400,000 shares ($940,698,279).
Net asset value per share was $145.44 on 11,323,603 shares outstanding.
MVB Financial furnished Q3 2026 investor presentation slides under Regulation FD, with the slides attached as Exhibit 99.1 to an 8-K dated October 29, 2026. The slides show nine-month net interest income of $93.3 million, up from $79.0 million a year earlier, and a Q3 2026 net interest margin of 4.02% on a fully tax-equivalent basis. Tangible book value per share was $25.26 versus $26.17 in 2025, and the company cites a roughly $1.44 per share impact from changes in accumulated other comprehensive income since December 31, 2025.
Nine-month net interest income was $93.3 million in 2026 versus $79.0 million in 2025.
Q3 2026 net interest margin on a fully tax-equivalent basis was 4.02%, up 47 basis points from Q3 2025.
Total assets were $3.5 billion at Q3 2026, with total loans of $2.5 billion and total deposits of $3.1 billion.
Tangible book value per share was $25.26 in 2026 versus $26.17 in 2025; the company cites about $1.44 per share from accumulated other comprehensive income changes since December 31, 2025.
Celestica furnished an Investor and Analyst Day presentation as Exhibit 99.1 to this 8-K, to be used with a conference call on October 27, 2026 about its results for the quarter ended September 30, 2026. The presentation shows full-year 2025 revenue rose to $12.4 billion from $9.6 billion in 2024, and diluted earnings per share rose to $7.16 from $3.61.
FY 2025 revenue was $12,390.9 million, up from $9,646.0 million in FY 2024.
FY 2025 GAAP net earnings were $832.5 million, compared with $428.0 million in FY 2024.
FY 2025 diluted EPS was $7.16, compared with $3.61 in FY 2024; non-GAAP adjusted diluted EPS was $6.05.
The conference call on October 27, 2026 covers Q3 2026 results and the Investor and Analyst Day.
Aclaris Therapeutics reported primary analysis results from two small Phase 1b proof-of-concept trials of its bispecific antibody ATI-052, in atopic dermatitis (14 patients) and asthma (16 patients). The company also estimated unaudited cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026, and said it will prioritize development in eosinophilic esophagitis with a Phase 2b trial planned for early 2027.
Atopic dermatitis trial: 45% placebo-adjusted mean EASI improvement at day 57, from a per-protocol population of nine active-arm and one placebo-arm patient
Asthma trial: 59% mean FeNO reduction at day 15 in the ATI-052 arm versus 15% in the placebo arm, with 16 patients enrolled
Estimated cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026; figure is unaudited and may change
Company plans to start a Phase 2b trial in eosinophilic esophagitis in early 2027
Oruka Therapeutics reported Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001 in moderate-to-severe plaque psoriasis. In the 600 mg group, 61% of patients reached PASI 100, the primary endpoint, versus 0% on placebo (p<0.0001), and the company plans to start Phase 3 trials in the first half of 2027 using that dose. The company also reported that cash, equivalents and marketable securities were $1.1 billion as of June 30, 2026.
61% of high-dose (600 mg) patients achieved PASI 100 at Week 16, versus 0% on placebo (p<0.0001); 86% achieved PASI 90 and IGA 0/1.
Treatment-emergent adverse events occurred in 39% of high-dose patients and 43% of placebo patients; no serious TEAEs occurred in the high-dose group.
Phase 3 trials are planned to start in the first half of 2027 with the 600 mg dose, subject to regulatory interactions.
52-week EVERLAST-A results are expected in December 2026; cash of $1.1 billion as of June 30, 2026 is expected to fund operations through an anticipated BLA filing.
Perspective Therapeutics reported updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET in advanced SSTR2-expressing neuroendocrine tumors, presented at the ESMO Congress 2026 on October 23, 2026. The company reported objective response rates of 33% in Cohort 2 and 50% in Cohort 3, with no dose-limiting toxicities and no discontinuations due to adverse events, and it aims to complete Phase 3 site start-up preparations around year-end 2026. The data are early and based on small cohorts, so the results may not hold as the trial continues.
Objective response rate was 33% (15 of 46) in Cohort 2 at 5.0 mCi and 50% (10 of 20) in Cohort 3 at 6.0 mCi, including unconfirmed responses
Progression-free survival was 72% at 18 months across all patients who received at least one treatment
20 of 68 patients (29%) had high-grade treatment-emergent adverse events, all Grade 3; no dose-limiting toxicities were reported
Phase 3 site start-up preparations targeted around year-end 2026, with Phase 3 initiation expected in 2027 following an End-of-Phase 2 meeting with the FDA
Bread Financial reported September 2026 credit metrics, including a delinquency rate of 5.57%, down from 6.04% a year earlier. Average credit card and other loans rose 6.4% year over year for the month, to $18.74 billion. The release does not include revenue, earnings or guidance, and the filing gives no prior-year comparison for net principal loss rates.
Delinquency rate was 5.57% as of September 30, 2026, versus 6.04% as of September 30, 2025.
Net principal loss rate was 5.99% for September 2026 and 6.40% for the three months ended September 30, 2026.
Average credit card and other loans rose 6.4% year over year for September to $18.74 billion; end-of-period loans were $18.85 billion.
NETSTREIT furnished an updated third quarter 2026 investor presentation under Regulation FD, attached as Exhibit 99.1 and posted on its website. The deck includes unaudited Q3 2026 results showing higher revenue and net income than in Q3 2025, along with portfolio, liquidity and balance sheet data as of September 30, 2026.
Total revenues for the three months ended September 30, 2026 were $66.3 million, compared with $48.3 million a year earlier.
Net income attributable to common stockholders was $8.5 million, compared with $0.6 million in the prior-year quarter.
Diluted earnings per share were $0.08, compared with $0.01 a year earlier.
Total liquidity was $1.3 billion and unsettled forward equity was $312 million as of September 30, 2026.
Zedge furnished an investor presentation under Item 7.01 for use at an investor conference and posting on its website. The deck describes a pivot toward DataSeeds, a business selling AI training data, and reports that insiders led a roughly $7.7 million financing, with Howard Jonas contributing $6.5 million of it. The presentation also shows year-to-date revenue up 9% to $23.9 million, alongside a GAAP net loss of $0.6 million.
Year-to-date revenue of $23.9 million, up 9%, through Q3 FY26 per the presentation
Insider-led investment of about $7.7 million, of which $6.5 million was associated with Howard Jonas
Morris Berger has been Chief Executive Officer since October 1, 2026; Jonathan Reich is President and Chief Operating Officer
Presentation states the stock buyback was suspended and the quarterly dividend is expected to continue
At its 2026 Investor Meeting on October 19, 2026, Jefferies presented trailing 12-month results that management described as strong, including net revenues of $8.5 billion, net earnings above $935 million, and a return on tangible equity of 13.1%. Management said it expects investment banking and capital markets margins to keep expanding and that it expects to close the Hildene transaction in the first quarter of 2027.
Trailing 12-month net revenues of $8.5 billion, net earnings over $935 million, and return on tangible equity of 13.1%
Investment banking and capital markets segment revenue rose from $4.5 billion in 2023 to $7.8 billion, and pre-tax profit rose from $500 million to about $1.3 billion
Over $925 million returned to shareholders in the current year through buybacks and dividends
Management expects to close the Hildene transaction in the first quarter of 2027
NexMetals reported an updated mineral resource estimate for Selebi North, one of two deposits at its past-producing Selebi mines in Botswana, showing indicated resources of 8.95 million tonnes, up from 3.00 million tonnes in 2024. The company also said it is allowing more time for the Selebi preliminary economic assessment and is still reviewing project funding, and the filing contains no revenue, earnings or production timeline. The estimate contains no mineral reserves and does not establish economic viability.
Selebi North indicated mineral resources rose to 8.95 million tonnes from 3.00 million tonnes in 2024, a 198% increase.
Selebi North inferred mineral resources rose 63% to 9.48 million tonnes from 5.83 million tonnes in 2024.
Combined Selebi indicated resources are 8.95 million tonnes and inferred resources are 41.95 million tonnes, as of October 16, 2026, prepared by The MSA Group.
The project funding review with National Bank of Canada Capital Markets is ongoing, and the company states there is no guarantee it will result in a transaction.
Kearny Financial Corp. filed an investor presentation for its fiscal 2026 Annual Meeting of Stockholders on October 20, 2026, as Exhibit 99.1. The deck reviews fiscal year 2026 results, which ended June 30, 2026, and the company's strategic outlook, and it is furnished rather than filed under Regulation FD.
Fiscal 2026 net income was $36.3 million, up 39%, and net interest income grew 15.1%, per the presentation.
Pre-tax, pre-provision earnings per share grew 47%, according to the deck.
Fiscal 2026 net charge-offs were 4 basis points, and KRNY's 12-month total return was 55.8% versus 29.3% for the KBW NASDAQ Regional Bank index.
Stockholder votes cover four director elections, ratification of Crowe LLP as auditor for the year ending June 30, 2027, and an advisory vote on executive compensation.
Synchrony Financial filed monthly credit statistics for the thirteen months through September 30, 2026, as an unaudited exhibit to an 8-K. For September 2026, the net charge-off rate was 4.7%, down from 5.3% in September 2025, and the 30+ day delinquency rate was 4.3%, down from 4.4%. The company said it will keep publishing these figures monthly, with quarter-end months released alongside its earnings.
Net charge-off rate was 4.7% for September 2026, versus 5.3% for September 2025.
Adjusted net charge-off rate, a non-GAAP measure, was 4.6% for September 2026, versus 5.1% a year earlier.
30+ day delinquency rate was 4.3% at September 30, 2026, versus 4.4% at September 30, 2025.
Period-end loan receivables were $103.3 billion at September 30, 2026, versus $100.2 billion a year earlier.
Jefferies Financial Group posted an investor presentation on its website for its October 19, 2026 investor meeting, furnished as Exhibit 99.1 to a Form 8-K. The deck reports trailing-twelve-month results through the third quarter of 2026, including $8.5 billion in net revenues and $0.9 billion in net earnings to all shareholders, and it reviews its pending acquisition of Hildene/SILAC and a planned Japan Equities joint venture with SMBC.
Presentation posted October 19, 2026 for the company's October 19, 2026 Investor Meeting; filed as Exhibit 99.1
LTM Q3'26 net revenues of $8.5 billion, up 119% since 2019; net earnings to all shareholders of $0.9 billion, up 123% since 2019
Pending acquisition: Jefferies intends to acquire a 50% interest in Hildene Holding Company, which is acquiring SILAC, as disclosed in September 2025
Japan Equities joint venture with SMBC is scheduled to launch January 1, 2027
Fractyl Health reported topline six-month results from the Pivotal Cohort of its REMAIN-1 study of the Revita DMR System, a randomized, double-blind, sham-controlled trial. The company said Revita met its six-month co-primary endpoint, with participants retaining about 80% of GLP-1-induced weight loss versus 67% for sham, and the company plans a De Novo marketing application to the FDA in late Q4 2026.
Six-month co-primary endpoint met in the mITT population (N=308) with p=0.0023; weight regain of 5.1% for Revita versus 8.2% for sham
Post hoc analysis: participants receiving 20 cm or more of ablation had a mean weight regain of 3.8% (n=47); the second co-primary endpoint at 12 months is expected in Q1 2027
No device- or procedure-related serious adverse events, no deaths, and no unanticipated adverse device effects as of the September 24, 2026 data cut-off
Potential U.S. De Novo submission planned for late Q4 2026; potential U.S. launch in early 2028 if authorized
Opus Genetics presented interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy trials at Retina in Rio 2026 on October 14, 2026, and furnished the press release and slides in this 8-K. The company said the data are interim and based on small participant groups, and it expects Phase 3 dosing for OPGx-LCA5 to begin in the fourth quarter of 2026.
OPGx-BEST1 low-dose Cohort 1: three of four evaluable participants (75%) showed improved retinal sensitivity in the treated transitional zone.
OPGx-LCA5 adults showed sustained improvements in visual acuity and light sensitivity through 24 months; three pediatric participants showed results through six months.
OPGx-BEST1 high-dose Cohort 2 has completed enrollment with 11 participants.
Phase 3 dosing for OPGx-LCA5 is expected in the fourth quarter of 2026.
Gulf Resources said it received approval from the Shouguang Municipal Government to resume production at its Factories No. 2 and No. 10. The company expects to complete test and trial production in the fourth quarter of 2026 and believes the factories will produce revenue in the first half of 2027.
Approval from the Shouguang Municipal Government to resume production at Factories No. 2 and No. 10, announced October 14, 2026
Preparation work, including upgrades to some facilities, to begin immediately, with test and trial production expected to be completed in Q4 2026
Revenue from the factories expected in the first half of 2027
Company states resumption would raise annual production capacity by more than 20%, citing its 2025 Form 10-K
SSR Mining filed an updated Technical Report Summary for its Marigold Complex in Nevada, with an effective date of May 1, 2026, and a signature date of October 9, 2026. The report puts total Marigold mineral reserves at 3.96 million ounces of gold, which the filing says is a 73% increase in contained gold over previous estimates, driven by a $2,200 per ounce gold price assumption. The report also notes that Buffalo Valley mining operations are currently unpermitted and depend on permits being secured before planned production begins in 2029.
Marigold Probable Reserves of 240.44 million tonnes grading 0.46 g/t Au, containing 3.52 million ounces; total reserves including stockpiles and leach pad inventory are 3.96 million ounces
The filing says the updated $2,200 per ounce gold price assumption triggered a 73% increase in contained gold versus previous estimates
Buffalo Valley contributes 45.33 million tonnes of Probable Reserves containing 0.67 million ounces, but mining there is currently unpermitted and production is scheduled to begin in 2029
VAALCO reported operational updates for the third quarter of 2026, including completion of its offshore Gabon Phase 3 drilling program and a stabilized initial flow rate of about 2,000 gross barrels of oil per day from the ETSEM-3H well. The Baobab Phase 5 drilling program in Côte d'Ivoire has started, with the first new producer expected online near the end of 2026, and the filing does not include financial results such as revenue or earnings.
ETSEM-3H well in the SE Etame field flows about 2,000 gross BOPD, or 1,140 BOPD net to Vaalco
Phase 3 drilling program is complete and the Borr Norve rig has been demobilized from the field
Baobab Phase 5 drilling has begun; plan calls for four producers, three water injectors and two workovers
First new Baobab producer expected online near end of 2026, with meaningful production growth expected in 2027
Forward Industries said it added 948,601 SOL in its fiscal fourth quarter ended September 30, 2026, raising holdings 13% to 8,501,298 SOL, with purchases at an average cost of $83 per SOL. SOL per fully diluted share rose to 0.0806 from 0.0730 over the quarter, while net asset value increased to $870.4 million and institutional debt rose to $167.5 million, and the company said part of the purchases was funded by selling FWDI shares. All figures are preliminary and unaudited and remain subject to the company's annual audit.
SOL and SOL equivalents rose by 948,601 (13%) to 8,501,298 as of September 30, 2026, from 7,552,698 on June 30, 2026.
SOL per fully diluted share increased to 0.0806 from 0.0730, quarterly growth of 10.4% or about 42% annualized.
Net asset value was $870,382,702 as of September 30, 2026, up from $481,328,023; institutional debt rose to $167.5 million from $105 million.
Figures are preliminary and unaudited and remain subject to completion of the annual audit.
NexMetals reported an updated Mineral Resource Estimate for Selebi Main, one deposit at its past-producing Botswana copper-nickel-cobalt mine, with 32.47 million tonnes in the Inferred category, up 72% from the Selebi Main portion of its 2024 estimate. The Selebi North estimate is still in progress and is not included, and the filing says the resource is not a mineral reserve and may never be mined economically.
Selebi Main tonnage rose to 32.47 million tonnes, grading 1.53% copper and 0.97% nickel, versus 18.89 million tonnes in the 2024 estimate.
Contained copper increased 55% to 495,400 tonnes and contained nickel increased 91% to 316,800 tonnes; cobalt is now included.
The company reported approximately $10.5 million in cash at September 30, 2026.
A NI 43-101 Technical Report is to be filed within 45 days of the October 1, 2026 release.
Q32 Bio said on September 30, 2026 that additional 36-week results and initial 16-week off-drug findings from Part B of its open-label SIGNAL-AA Phase 2a trial of bempikibart were presented at the EADV Congress 2026. The Part B study enrolled 33 patients with severe or very severe alopecia areata, and the company plans to start a registration-directed program in the first half of 2027, subject to regulatory discussions in the second half of 2026.
At Week 36, mean SALT score reduction from baseline was 35.3% in the mITT analysis, and 40.0% (10/25) of mITT patients achieved a SALT-20 response.
At the 16-week off-drug time point, 44% of patients achieved SALT-20, 61% achieved SALT 30 and 50% achieved SALT 50 (18 patients entered this period).
The company reported no serious adverse events or Grade 3 or higher treatment-related adverse events; injection site reactions were the most common treatment-emergent adverse event at 36.3%.
Q32 Bio plans regulatory discussions in the second half of 2026, a registration-directed program in the first half of 2027, and expects Part B open-label extension data in the second half of 2027.
Tectonic Therapeutic reported topline Phase 1a results for TX2100, an investigational antibody for hereditary hemorrhagic telangiectasia (HHT), stating the drug was generally safe and well-tolerated in healthy adult volunteers. The FDA also granted TX2100 Fast Track designation for HHT and cleared the IND for a planned Phase 1b trial, which advances the clinical program toward patients. The filing discloses no revenue or financial results, and anti-drug antibody results remain pending.
Phase 1a enrolled 48 healthy adult volunteers across six dose cohorts; no deaths, serious adverse events or severe treatment-emergent adverse events were reported at any dose
FDA cleared the IND in August 2026 and granted Fast Track designation in September 2026
Phase 1b trial in HHT patients planned to begin by year-end 2026; Phase 2 planned to begin in early 2027
Detailed Phase 1a results to be presented at the CureHHT 16th HHT International Scientific Conference, October 12-16, 2026
Adicet Bio reported preliminary Phase 1 data for prula-cel, an investigational cell therapy, in 22 efficacy-evaluable patients with systemic lupus erythematosus, with or without lupus nephritis, using an August 28, 2026 data cut-off. The company plans to start pivotal study start-up activities for lupus nephritis in the fourth quarter of 2026, and the filing says the high DORIS remission rate may support including lupus patients without nephritis. The data are early, from a small group, and the filing contains no revenue or cash figures.
22 efficacy-evaluable patients (16 with lupus nephritis, 6 with extra-renal SLE); follow-up ranged from 6 to 21 months; data cut-off August 28, 2026.
At 12 months, 50% of evaluable lupus nephritis patients achieved a complete renal response and 54% of evaluable patients achieved DORIS remission.
Among 24 safety-evaluable patients, no cytokine release syndrome above Grade 2 was reported; Grade 1 or 2 CRS occurred in 25%; infections occurred in 54%, with Grade 3 or higher in 8.3%.
Pivotal lupus nephritis study start-up activities are planned for Q4 2026; a mid-2027 clinical data update in LN/SLE is anticipated.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.